Aralez Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Aralez Pharmaceuticals's estimated annual revenue is currently $2.4M per year.
- Aralez Pharmaceuticals's estimated revenue per employee is $100,500
- Aralez Pharmaceuticals's total funding is $350M.
Employee Data
- Aralez Pharmaceuticals has 24 Employees.
- Aralez Pharmaceuticals grew their employee count by -25% last year.
Aralez Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Product Manager | Reveal Email/Phone |
Aralez Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $18.5M | 92 | -1% | N/A | N/A |
#2 | $14.3M | 71 | 6% | N/A | N/A |
#3 | $36M | 179 | 8% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $17.9M | 93 | 3% | $192.2M | N/A |
#6 | $64.9M | 323 | 4% | N/A | N/A |
#7 | $0.5M | 5 | -55% | N/A | N/A |
#8 | $6.8M | 34 | -41% | N/A | N/A |
#9 | $19.5M | 97 | 23% | N/A | N/A |
#10 | $2.5M | 25 | 19% | N/A | N/A |
What Is Aralez Pharmaceuticals?
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. We concentrate mainly on the development phase of a drug's life. We believe that there are and will continue to be more and more opportunities in need of rapid development. Our initial focus is developing products for migraine therapy, a multi-billion dollar global market. POZEN has three product candidates, each designed with a unique profile to treat different stages of migraine attacks - mild, moderate and severe. Combined, these product candidates may offer patients and physicians the ability to customize migraine therapy. We plan to work with partners to commercialize our product candidates, which we project to have a combined market potential of more than $1 billion.
keywords:N/A$350M
Total Funding
24
Number of Employees
$2.4M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aralez Pharmaceuticals News
Athira Pharma Michael A. Panzara, M.D., CMO and head of ... roles within Aerie Pharmaceuticals, Aralez Pharmaceuticals and Cubist...
David Enloe, CEO of Societal CDMO (formerly Recro Pharma) ... leadership roles within Aerie Pharmaceuticals, Aralez Pharmaceuticals and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.2M | 24 | 0% | N/A |
#2 | $2.4M | 24 | N/A | N/A |
#3 | $2.5M | 25 | 19% | N/A |
#4 | N/A | 26 | 24% | N/A |
#5 | $5.3M | 26 | 0% | N/A |